HBQ Stock Overview Operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Hofseth BioCare ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for Hofseth BioCare Historical stock prices Current Share Price NOK 0.13 52 Week High NOK 0.25 52 Week Low NOK 0.074 Beta 0.36 1 Month Change 19.46% 3 Month Change 5.60% 1 Year Change -44.07% 3 Year Change -80.59% 5 Year Change -85.37% Change since IPO -48.24%
Recent News & Updates
Hofseth BioCare ASA, Annual General Meeting, May 23, 2025 Nov 11
Third quarter 2024 earnings released: kr0.09 loss per share (vs kr0.057 loss in 3Q 2023) Nov 09
Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026 Nov 09 Hofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025 Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO Oct 22
New minor risk - Shareholder dilution Aug 26 See more updates
Hofseth BioCare ASA, Annual General Meeting, May 23, 2025 Nov 11
Third quarter 2024 earnings released: kr0.09 loss per share (vs kr0.057 loss in 3Q 2023) Nov 09
Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026 Nov 09 Hofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025 Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO Oct 22
New minor risk - Shareholder dilution Aug 26
Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023) Aug 25
Less than half of directors are independent Jun 11
Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022) Apr 25
Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022) Apr 21
Hofseth BioCare ASA Announces Board Changes Mar 15
Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022) Feb 11
Now 31% undervalued after recent price drop Nov 30 Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025
Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022) Nov 12
New minor risk - Market cap size Oct 05
Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022) Aug 27
New minor risk - Market cap size Jun 13
Hofseth Biocare ASA Announces the Online Publication of Its Abstract May 31
First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022) May 14
Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021) Feb 12 Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023
Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021) Nov 13
Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA Aug 30
Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021) Aug 27
Hofseth BioCare ASA Announces Executive Changes Jul 29
First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021) May 07
Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020) Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 05
Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA Dec 05
Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020) Nov 06
Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020) Aug 28
Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022 Aug 27
First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020) May 22
Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019) Mar 21
Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019) Feb 06
New 90-day high: €0.91 Jan 26
Chief Executive Officer recently bought €48k worth of stock Jan 02
Chief Executive Officer recently bought €48k worth of stock Jan 01
Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million. Dec 20
Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products Dec 12
Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea Dec 10
Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD Dec 03
New 90-day high: €0.82 Dec 02
Hofseth Biocare ASA Hires Andy Gill as VP from January 2021 Nov 30 Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021
Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee Nov 12
Third quarter earnings released Oct 30
New 90-day low: €0.69 Oct 21
HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport Oct 19
Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million. Oct 18
Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US Oct 13
Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19 Sep 24
New 90-day low - €0.75 Sep 16
First half earnings released Aug 31
Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million. Aug 28 Shareholder Returns HBQ DE Biotechs DE Market 7D 14.8% -2.9% -2.6% 1Y -44.1% -14.7% 6.9%
See full shareholder returns
Return vs Market: HBQ underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is HBQ's price volatile compared to industry and market? HBQ volatility HBQ Average Weekly Movement 25.3% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HBQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HBQ's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Show more Hofseth BioCare ASA Fundamentals Summary How do Hofseth BioCare's earnings and revenue compare to its market cap? HBQ fundamental statistics Market cap €53.38m Earnings (TTM ) -€11.29m Revenue (TTM ) €20.99m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HBQ income statement (TTM ) Revenue NOK 248.08m Cost of Revenue NOK 187.72m Gross Profit NOK 60.36m Other Expenses NOK 193.83m Earnings -NOK 133.48m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) -0.32 Gross Margin 24.33% Net Profit Margin -53.80% Debt/Equity Ratio 189.8%
How did HBQ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 22:49 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hofseth BioCare ASA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonas Peciulis Norne Securities AS Henning Steffenrud Swedbank Norway
Show 0 more analysts 
